Commence Phase 2 trial combining VIR-3434 and VIR-2218
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 28 Jan 2021
- Due
- 31 Dec 2021
- Delivered
- July 2021
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“A Phase 2 trial combining VIR-3434 with Vir’s HBV-targeting siRNA, VIR-2218, is expected to commence in the second half of this year.”
What we found
Evidence strength A What the grades mean
The company initiated the Phase 2 MARCH trial, which evaluates the combination of VIR-2218 and VIR-3434, in July 2021, meeting the commitment to commence the trial in the second half of 2021.
-
A Vir Biotechnology, Inc. 10-K filed 2022-02-28
“In July 2021, we initiated the Phase 2 Monoclonal Antibody siRNA Combination against Hepatitis B, or MARCH, trial to evaluate the combination of VIR-2218 and VIR-3434 as a functional cure regimen for chronic HBV infection.” ✓ confirmed on the page
Checked 25 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Product other
- Indicative materiality
- Low rules
- Action
- Commence
- Deliverable
- Phase 2 trial of VIR-3434 and VIR-2218
- Language
- Aspirational (“aims”, “intends”)
- In the company’s control
- Medium
- Specificity
- High
- Depends on
- Regulatory
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Vir Biotechnology, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-VIR-022589 · Corrections policy